Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission ...
JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...
TipRanks on MSN
Alpha Tau Medical unveils strong pancreatic cancer Alpha DaRT data ahead of ASCO GI 2026
An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the FDA ...
Alpha Tau Medical’s proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers. Alpha Tau is waiting for FDA feedback to initiate a US pivotal trial in ...
Radioactive decay produces three flavors of emissions: alpha, beta, and gamma. Alpha particles comprise 2 neutrons and 2 protons. Because of their large mass and relatively slow speed, alpha particles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results